ArticleMedical science monitor : international medical journal of experimental and clinical research2026
Prognostic Value of Albumin-Bilirubin Score in Acute Pancreatitis: Insights From the MIMIC-IV Database.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND This study examined the association of the albumin-bilirubin (ALBI) score with short-term and long-term prognoses in individuals with acute pancreatitis (AP), using the MIMIC-IV database. MATERIAL AND METHODS A retrospective cohort study was conducted using MIMIC-IV (V3.0). ALBI score was calculated based on albumin and bilirubin serum levels. Patients were divided into 3 groups according to threshold values of ALBI at -2.60 and -1.39. Primary and secondary outcomes were 30-day and 1-year all-cause mortality, respectively. A multivariable Cox proportional hazards model assessed the association between ALBI and mortality risk. Restricted cubic spline analysis was used to explore their nonlinear relationship. Kaplan-Meier curves compared survival, and subgroup analyses evaluated interaction effects. RESULTS A total of 1953 AP patients were included. Results indicated each unit increase in ALBI score was associated with a higher risk of mortality (30-day: HR, 1.37; 95% CI, 1.16-1.61; P<0.001; 1-year: HR, 1.17; 95% CI, 1.03-1.33; P=0.018). Kaplan-Meier curves showed significant differences in survival (log-rank P<0.001). Restricted cubic spline analysis identified a nonlinear association between ALBI score and risk of mortality, with a turning point at -2.3, beyond which the risk of mortality increased sharply. Subgroup analysis indicated stronger associations in patients not receiving carbapenems or fluoroquinolones or requiring mechanical ventilation within the first 24 hours of ICU admission, suggesting ALBI may reflect risk of mortality in these patients, with no significant association observed in those receiving these treatments. CONCLUSIONS ALBI score correlates with AP prognosis, supporting its use in early risk stratification and personalized management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.